Relapsing Refractory Multiple Myeloma Epidemiology Forecast 2026-2035

Relapsing refractory multiple myeloma (RRMM) represents a challenging stage of disease progression with limited treatment durability. According to Evangelos Mavrothalassitis et al., 2025, approximately 160,000 global multiple myeloma cases and 106,000 deaths were reported in 2018, with an incidence of 7.0 per 100,000. According to relapsing refractory multiple myeloma epidemiology forecast, disease burden is expected to rise steadily.

Relapsing Refractory Multiple Myeloma Epidemiology Forecast Report Coverage

The analyst's “Relapsing Refractory Multiple Myeloma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of relapsing refractory multiple myeloma. It projects the future incidence and prevalence rates of relapsing refractory multiple myeloma cases across various populations. The study covers age, gender, and type as major determinants of the relapsing refractory multiple myeloma population. The report highlights patterns in the prevalence of relapsing refractory multiple myeloma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of relapsing refractory multiple myeloma in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Relapsing Refractory Multiple Myeloma Understanding: Disease Overview

Relapsing refractory multiple myeloma (RRMM) is an advanced form of multiple myeloma, a malignant plasma cell disorder characterized by uncontrolled proliferation of abnormal plasma cells in the bone marrow. The condition is termed “relapsed” when the disease returns after prior therapy, and “refractory” when it no longer responds to treatment. RRMM occurs due to clonal evolution and drug resistance mechanisms, including genetic mutations and microenvironmental changes. While multiple myeloma has subtypes such as smoldering and active disease, RRMM represents a progressive, treatment-resistant stage associated with worsening organ damage and increased disease burden.

Relapsing Refractory Multiple Myeloma Epidemiology Perspective

The relapsing refractory multiple myeloma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the relapsing refractory multiple myeloma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for relapsing refractory multiple myeloma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Arooj Ahmed et al., 2023, multiple myeloma represents 1.8% of all new cancer cases and 2.1% of cancer deaths annually in the United States, with incidence rates of 4.5-6 per 100,000, showing a 126% global increase since 1990 and over 40% rise in the United States.
• As per Arooj Ahmed et al., 2023, the median age at diagnosis is approximately 70 years, with disease burden concentrated in elderly populations, while about one-third of patients are diagnosed at age 75 years or older, reflecting strong age-related epidemiological patterns.
• According to Mohammad Amin Ansarian et al., 2025, males account for nearly 57% of multiple myeloma cases, indicating higher susceptibility compared to females, influenced by biological factors such as loss of the Y chromosome and differing hormonal and immune responses.
• According to Arooj Ahmed et al., 2023, mortality has decreased by 14% in the United States but increased by 94% globally, while five-year survival rates have more than doubled due to advanced therapies, although early relapse is associated with significantly poorer overall survival outcomes.
• As per Oren Pasvolsky et al., 2025, relapsed/refractory multiple myeloma shows declining treatment response with successive therapy lines, with complete response rates falling from 32% in first-line therapy to 2% in fifth-line therapy, and median survival significantly lower in early relapse cases.

Country-wise Relapsing Refractory Multiple Myeloma Epidemiology

The relapsing refractory multiple myeloma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the United States, United Kingdom, Germany, France, Spain, Italy, Japan, and India, the epidemiology of relapsing refractory multiple myeloma reflects broader multiple myeloma trends with regional variation. According to Arooj Ahmed et al., 2023, multiple myeloma accounts for 1.8% of new cancer cases and 2.1% of cancer deaths annually in the United States, with an incidence of 4.5-6 per 100,000, while Western Europe reports similarly high age-standardized incidence rates. As per the study, incidence has risen globally by 126% since 1990, with comparatively lower but increasing rates in Japan and India, indicating expanding patient pools and subsequent increase in relapse burden.

Relapsing Refractory Multiple Myeloma: Treatment Overview

The relapsing refractory multiple myeloma treatment focuses on prolonging survival, controlling symptoms, and overcoming drug resistance. Common approaches include combination regimens involving proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Advanced therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies have shown significant efficacy in heavily pretreated patients. Additional options include corticosteroids, targeted therapies, and autologous stem cell transplantation in eligible individuals. Treatment selection depends on prior therapies, patient health status, and disease progression, with an emphasis on personalized and sequential treatment strategies.

Key Questions Answered

• What are the key findings of relapsing refractory multiple myeloma epidemiology in the 8 major markets?
• What will be the total number of patients with relapsing refractory multiple myeloma across the 8 major markets during the forecast period?
• What was the country-wise relapsing refractory multiple myeloma epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of relapsing refractory multiple myeloma patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of relapsing refractory multiple myeloma during the forecast period of 2026-2035?
• What are the currently available treatments for relapsing refractory multiple myeloma?
• What are the disease risks, signs, symptoms, and unmet needs of relapsing refractory multiple myeloma?

Scope of the Relapsing Refractory Multiple Myeloma Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of relapsing refractory multiple myeloma based on several factors.
• Relapsing Refractory Multiple Myeloma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The relapsing refractory multiple myeloma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.